Suggested remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia in non-transfusion dependent beta-thalassaemia.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
- ID number:
- 3870
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 February 2022 | Note added to the project documents |
| 10 November 2021 - 08 December 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual